These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8937965)

  • 41. Activity of third generation cephalosporins against Pseudomonas aeruginosa in high risk hospital units.
    Puri J; Revathi G; Kundra P; Talwar V
    Indian J Med Sci; 1996 Jul; 50(7):239-43. PubMed ID: 8979542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility testing of Pseudomonas aeruginosa by the Vitek 2 system: a comparison with Etest results.
    Saegeman V; Huynen P; Colaert J; Melin P; Verhaegen J
    Acta Clin Belg; 2005; 60(1):3-9. PubMed ID: 15981697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G; Zarakolu P; Hasçelik G; Akova M
    Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.
    Vahaboglu H; Saribaş S; Akbal H; Ozturk R; Yucel A
    J Antimicrob Chemother; 1998 Aug; 42(2):269-70. PubMed ID: 9738851
    [No Abstract]   [Full Text] [Related]  

  • 45. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
    Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
    J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparative evaluation of 2 methods--dilution in agar and diffusion in agar--in determining Pseudomonas aeruginosa sensitivity to antibiotics].
    Gabrielian SA; Bogdanova LF; Vorob'eva LS; Givental' NI
    Antibiot Med Biotekhnol; 1985 Jul; 30(7):511-6. PubMed ID: 3931545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa.
    Hamada Y; Sutherland CA; Nicolau DP
    J Clin Microbiol; 2015 May; 53(5):1712-4. PubMed ID: 25694527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial resistance of Pseudomonas aeruginosa strains isolated from surgical infections in a 7-year period at a general hospital in Venezuela.
    Rodriguez CN; Rodriguez-Morales AJ; Garcia A; Pastran B; Meijomil P
    Surg Infect (Larchmt); 2006 Jun; 7(3):269-73. PubMed ID: 16875460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the E test in testing susceptibility of Pseudomonas aeruginosa to tobramycin.
    Rautelin H; Renkonen I; Renkonen OV
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):177-80. PubMed ID: 1396734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
    Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative in vitro susceptibility of Burkholderia Pseudomallei to cefpirome, ceftazidime and cefepime.
    Seymour-Murray J; Norton R; Ashhurst-Smith C
    Pathology; 1997 Aug; 29(3):329-30. PubMed ID: 9271030
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Manduru M; Mihm LB; White RL; Friedrich LV; Flume PA; Bosso JA
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2053-6. PubMed ID: 9303416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
    Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility of Pseudomonas aeruginosa isolates to ceftazidime is unrelated to the expression of the outer membrane protein OprC.
    Pérez FJ; Navarro D; Gimeno C; García-de-Lomas J
    Chemotherapy; 1997; 43(1):27-30. PubMed ID: 8996738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.